NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved

BiondVax announced the completion of the clinical study report of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate. The trial in 120 adult volunteers was supported by the U.S. NIAID. As indicated when the preliminary trial data was published earlier this year, both primary objectives of the trial, to assess the safety and T cell immune responses to M–001, were achieved. The CSR concludes that 'M-001 was safe in this study' and that 'M-001 induced significant polyfunctional T cell responses.' In parallel, BiondVax's pivotal, clinical efficacy, Phase 3 trial in Europe is ongoing.